Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Turn Therapeutics Inc.

NASDAQ: TTRX · Life Sciences · 4 alerts · CIK 2023016

Share price
$8.55Close, Nov 16
Market cap
$261M
Shares outstanding
30.57MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Turn Therapeutics Inc. filings on SEC EDGAR ↗

8:06 AM ET 8-K
Investor Presentation

Turn Therapeutics Investor Presentation

Turn Therapeutics Inc. released an updated corporate investor presentation on November 10, 2026. The presentation provides a strategic overview of the company's operations and its PermaFusion technology platform. The filing was made under Item 7.01 to provide current information to the investment community.

7:02 AM ET 10-Q
Financial Results

Turn Therapeutics Q3 2026 Results: Net Loss of $6.23M, Loss Widens

Turn Therapeutics Inc. reported a net loss of $13.05 million for the nine months ended September 30, 2026, compared to $3.47 million in the prior year, driven largely by a $5.99 million loss from the change in fair value of derivative liabilities. The company significantly increased its cash position to $10.36 million following proceeds from the Avenue Capital Loan Agreement and common stock issuances.

Key figure
Net loss $6.23M
7:01 AM ET 8-K
Financial Results

Turn Therapeutics Financial Results

Turn Therapeutics reported Q3 2026 financial results and provided clinical updates on its GX-03 program for atopic dermatitis, noting that 59.3% of patients achieved clear skin in a Phase 2a trial. The company also announced the appointment of former CDC Director Robert R. Redfield as Chief Scientific Officer and expects its current cash to fund operations into Q3 2027.

Term
Q3 2026

“The results from our full Stage 1 trial population give us an important look at how patients responded to GX-03 across a wide range of disease severity and extent. We took what we learned from the initial trial and used it to refine our ongoing Phase 2b trial.”

Bradley Burnam, Chief Executive Officer

“The completed Stage 1 trial gives us a clearer picture of GX-03’s potential, particularly for patients with severe itching. We believe severe itch may also help strengthen confidence in an atopic dermatitis diagnosis, since other skin conditions can look similar on visual examination alone. Our Phase 2b trial is designed to find out whether those results can be repeated in a larger group of patients.”

Robert R. Redfield, M.D., Chief Scientific Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.